FDA clears Roche Cobas c 703, Cobas ISE Neo
March 31, 2026—The Food and Drug Administration granted 510(k) clearance to Roche’s Cobas c 703 and Cobas ISE Neo analytical units.
Webinars and Sponsored Roundtables — Register Now
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
Leica Biosystems launches next-gen Aperio GT Elite scanner
March 24, 2026—Leica Biosystems launched in the U.S. the Aperio GT Elite scanner and Aperio iQC software.
Siemens Healthineers launches RUO blood-based tau assays
March 20, 2026—Siemens Healthineers has launched the Atellica IM Phosphorylated tau 217 and Atellica IM Brain Derived Tau assays for research use.
Roche mass spec steroid assays categorized as moderate complexity
March 18, 2026—Roche received CLIA moderate complexity categorization for its Ionify steroid assays for mass spectrometry.
FDA clears Qiagen GI panels on QIAstat-Dx Rise
March 13, 2026—The Food and Drug Administration has cleared the Qiagen QIAstat-Dx Gastrointestinal Panel 2 and QIAstat-Dx GI Panel 2 Mini B and Mini B&V for use on the QIAstat-Dx Rise automated syndromic testing system.
MeMed BV Flex gets breakthrough device designation
March 12, 2026—The FDA has granted breakthrough device designation to MeMed’s BV Flex, a blood test designed to distinguish between bacterial and viral infections based on the body’s immune response.
Biocartis gets European IVDR certification for Idylla CDx MSI test
March 11, 2026—Biocartis’ Idylla CDx MSI test has received class C companion diagnostic certification under the European Union IVDR.
Agilent to acquire Biocare Medical for $950 million
March 9, 2026—Agilent Technologies has entered into a definitive agreement to acquire Biocare Medical in an all-cash transaction valued at $950 million.
Proscia earns top score in KLAS digital pathology report
March 4, 2026—A new report from KLAS Research awarded Proscia the highest overall performance score (95.2) in the U.S. market, based on customer feedback.
ARUP creates Innovation Central Laboratory
Feb. 26, 2026—ARUP Laboratories has launched the Innovation Central Laboratory to facilitate collaboration with pharmaceutical, biotechnology, and other industry partners.